CRISPR Therapeutics (CRSP) shares tumbled as much as 11.59% on Friday, hitting a low of $51.21, following a dismal earnings report and emerging competition in the gene therapy space. The company reported a first-quarter EPS of -$1.37, significantly worse than the anticipated -$1.15, while revenue cratered 97.8% year-over-year to just $0.86 million.

Regeneron's newly approved Otarmeni therapy, offered free to eligible U.S. patients, poses a direct challenge to CRISPR's Casgevy treatment. The competitive landscape is further clouded by insider selling, with CEO Samarth Kulkarni offloading 10,349 shares in March and total insider sales reaching 51,828 shares over three months.

Despite the selloff, analysts maintain a 'Moderate Buy' rating with a $64.53 average price target. The stock's volatility reflects broader uncertainties in the biotech sector, where pricing pressures and execution risks remain key concerns for investors.